secukinumab + methotrexate

A combination therapy comprised of **secukinumab**, a fully human monoclonal antibody targeting and neutralizing interleukin-17A (IL-17A), and **methotrexate**, a folate antimetabolite that inhibits several enzymes involved in nucleotide synthesis. Secukinumab is primarily used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and similar inflammatory conditions. Methotrexate is widely used as a disease-modifying antirheumatic drug (DMARD) and antineoplastic agent. Combination therapy is utilized in clinical practice, particularly in patients with psoriasis or psoriatic arthritis who have an inadequate response to monotherapy, with evidence supporting increased efficacy and sustained response. The mechanisms of action are complementary: secukinumab inhibits the pro-inflammatory IL-17A cytokine pathway, while methotrexate suppresses inflammation through inhibition of nucleotide synthesis and increased extracellular adenosine, leading to reduced immune activation[1][2][4][6].

Brand names

Cosentyx + methotrexatesecukinumab + methotrexate

Other names

secukinumab and methotrexateCosentyx and methotrexate